Agonists of different PPAR subtypes are known to be well established in the therapy of metabolic disorders such as obesity [15], insulin resistance, and atherosclerosis [16], which are inextricably linked to the development of MASLD and often develop simultaneously. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.